Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
460 On Other Exchanges
460 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

sihuan pharmaceutical hldgs (460) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIHUAN PHARMACEUTICAL HLDGS (460)

Related News

No related news articles were found.

sihuan pharmaceutical hldgs (460) Related Businessweek News

No Related Businessweek News Found

sihuan pharmaceutical hldgs (460) Details

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company offers various cardio-cerebral vascular drugs, such as Oudimei to treat dysfunction caused by cardiac and brain diseases; Kelinao/Anjieli/Qingtong to treat cardio, cerebro, and peripheral vascular diseases; Yuanzhijiu to treat cardio-cerebral vascular diseases; GM1 to treat traumatic brain injuries, cerebral vascular accidents, and Parkinson’s disease; Guhong to treat cerebrovascular problems; and Yimaining to treat chronic arteriosclerosis obliterans, unstable angina, myocardial infarction, coronary artery bypass surgery, cerebral infarction, ischemic spinal cord injury, diabetes, peripheral neuropathy, diabetes, and kidney diseases. It also offers Qu’Ao to treat brain cell dysfunction; Yeduojia primarily for peripheral nerve injuries; Chuanqing to treat ischemic cerebrovascular and coronary heart disease, cerebral embolism, vasculitis, and vascular dementia; Qu’Ao to treat brain cell dysfunction, traumatic brain injuries, and Alzheimer’s disease; and Danshen Chuanxiongqin to treat occlusive cerebrovascular diseases. In addition, the company provides Ren’Ao, a central nervous system drug; Luoanming, a metabolism drug; Bi’Ao and Zhuo’Ao to treat acute chronic respiratory diseases and to prevent lung infections after surgery; and Pojia, an anti-infective drug. Further, it is engaged in the further processing of agricultural and sideline products; construction of medical projects; and sale of medical appliances and supplies. The company distributes its products through a network of distributors and their sales force to hospitals and physicians. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is headquartered in Beijing, the People’s Republic of China.

2,726 Employees
Last Reported Date: 09/25/14
Founded in 2001

sihuan pharmaceutical hldgs (460) Top Compensated Officers

Deputy Chairman, Chief Executive Officer and ...
Total Annual Compensation: CNY16.0M
Co-Founder, Executive Chairman and Member of ...
Total Annual Compensation: CNY26.8M
Deputy General Manager of Sales & Marketing a...
Total Annual Compensation: CNY10.5M
Compensation as of Fiscal Year 2013.

sihuan pharmaceutical hldgs (460) Key Developments

Sihuan Pharmaceutical Holdings Group Ltd. Announces Delay in Publication of 2014 Annual Results

The Board of Sihuan Pharmaceutical Holdings Group Ltd. announced the shareholders of the company that the company is not able to publish the 2014 annual results on 31 March 2015 due to the fact that the auditors will not complete their audit of the company's financial statements in sufficient time.

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2014 Results on Mar 31, 2015

Sihuan Pharmaceutical Holdings Group Ltd. announced that they will report fiscal year 2014 results on Mar 31, 2015

Sihuan Pharmaceutical Holdings Group Ltd., Board Meeting, Mar 31, 2015

Sihuan Pharmaceutical Holdings Group Ltd., Board Meeting, Mar 31, 2015., at 11:00 China Standard Time. Agenda: To consider and approve the annual results of the Company and its subsidiaries for the year ended December 31, 2014; and to consider the recommendation of the payment of final dividend.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
460:HK $4.41 HKD 0.00

460 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 460.
View Industry Companies

Industry Analysis


Industry Average

Valuation 460 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIHUAN PHARMACEUTICAL HLDGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at